Conversely, K-ras mutations occur with equal frequency in tumors with and without hyperplasia, and the epidemiologic results seem to suggest that K-ras activation is associated with malignant progression of endometrial tumors without the need for transition via hyperplasia [11]. The gene discussed is KRAS; the disease is endometrium neoplasm.